within Pharmacolibrary.Drugs.ATC.J;

model J01DC03
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00198,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0106,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DC03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Cefamandole is a second-generation cephalosporin antibiotic, formerly used for the treatment of bacterial infections such as respiratory tract infections, urinary tract infections, and skin and soft tissue infections. It has activity against a broad spectrum of Gram-positive and Gram-negative bacteria. Due to concerns regarding safety, including hypoprothrombinemia and disulfiram-like reactions, and availability of safer alternatives, cefamandole is rarely used or approved today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics determined in healthy adult volunteers after single intravenous injection.</p><h4>References</h4><ol><li><p>Montesissa, C, et al., &amp; Carli, S (2003). Pharmacodynamics and pharmacokinetics of cefoperazone and cefamandole in dogs following single dose intravenous and intramuscular administration. <i>Veterinary journal (London, England : 1997)</i> 166(2) 170–176. DOI:<a href=&quot;https://doi.org/10.1016/s1090-0233(03)00051-0&quot;>10.1016/s1090-0233(03)00051-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12902182/&quot;>https://pubmed.ncbi.nlm.nih.gov/12902182</a></p></li><li><p>Neu, HC (1978). Comparison of the pharmacokinetics of cefamandole and other cephalosporin compounds. <i>The Journal of infectious diseases</i> 137 Suppl S80–S87. DOI:<a href=&quot;https://doi.org/10.1093/infdis/137.supplement.s80&quot;>10.1093/infdis/137.supplement.s80</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/650006/&quot;>https://pubmed.ncbi.nlm.nih.gov/650006</a></p></li><li><p>Berkhout, J, et al., &amp; Mattie, H (2003). Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion. <i>Antimicrobial agents and chemotherapy</i> 47(6) 1862–1866. DOI:<a href=&quot;https://doi.org/10.1128/AAC.47.6.1862-1866.2003&quot;>10.1128/AAC.47.6.1862-1866.2003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12760859/&quot;>https://pubmed.ncbi.nlm.nih.gov/12760859</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DC03;
